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BACKGROUND: Uterine serous papillary carcinoma (USPC) is a biologically aggressive variant of endometrial cancer. We investigated
the expression of Serum Amyloid A (SAA) and evaluated its potential as a serum biomarker in USPC patients.
METHODS: SAA gene and protein expression levels were evaluated in USPC and normal endometrial tissues (NEC) by real-time PCR,
immunohistochemistry (IHC), flow cytometry and by a sensitive bead-based immunoassay. SAA concentration in 123 serum samples
from 51 healthy women, 42 women with benign diseases, and 30 USPC patients were also studied.
RESULTS: SAA gene expression levels were significantly higher in USPC when compared with NEC (mean copy number by
RT–PCR¼162 vs 2.21; P¼0.0002). IHC revealed diffuse cytoplasmic SAA protein staining in USPC tissues. High intracellular levels
of SAA were identified in primary USPC cell lines evaluated by flow cytometry and SAA was found to be actively secreted in vitro.
SAA concentrations (mgml
 1) had a median (95% CIs) of 6.0 (4.0–8.9) in normal healthy females and 6.0 (4.2–8.1) in patients with
benign disease (P¼0.92). In contrast, SAA values in the serum of USPC patients had a median (95% CI) of 15.6 (9.2–56.2),
significantly higher than those in the healthy group (P¼0.0005) and benign group (P¼0.0006). Receiver operating characteristics
(ROC) analysis of serum SAA to classify advanced- and early-stage USPC yielded an area under the ROC curve of 0.837
(P¼0.0024).
CONCLUSION: SAA is not only a liver-secreted protein but is also a USPC cell product. SAA may represent a novel biomarker for
USPC to assist in staging patients preoperatively, and to monitor early-disease recurrence and response to therapy.
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Cancer of the uterine corpus is the most prevalent gynaecological
tumour in women, with an estimated 40100 cases and 7470 deaths
in the United States in 2008 (Jemal et al, 2008). Two subtypes of
endometrial carcinoma, namely type I and type II tumours, have
been described based on both clinical and histopathological
variables (Bohkman, 1983). Type I endometrial cancers, which
account for the majority of the cases, are usually well differentiated
and endometrioid in histology. These neoplasms are frequently
diagnosed in younger women, are associated with a history of
hyperestrogenism as the main risk factor, and typically have a
favourable prognosis with appropriate therapy. In contrast, type II
endometrial cancers are poorly differentiated tumours, often with
serous papillary (USPC) or clear cell histology. Although USPC
account for only a minority of endometrial cancers (i.e., less than
10%), about 40% of all relapses occur in this group of patients
(Hendrickson et al, 1982; Goff et al, 1994; Carcangiu and
Chambers, 1995; Chan et al, 2003). The discovery of novel
diagnostic and therapeutic markers against this aggressive subset
of endometrial cancers remains a high priority.
High-throughput genomic analysis represents a new tool for
the discovery of novel molecular tumour markers. Using this
technology, our group has recently evaluated the genetic
fingerprints of USPC (Santin et al, 2004, 2005). Among the several
candidate target genes identified, the gene encoding for human
serum Amyloid A (SAA), an HDL-associated lipoprotein known to
have a major role as a modulator of inflammation and in the
metabolism and transport of cholesterol (Yamada, 1999; Malle
et al, 2009), was consistently found as one of the top upregulated
genes in USPC. In humans the SAA gene family consists of three
genes (SAA1, SAA2, and SAA4) and a (pseudo) gene (SAA3) (Malle
et al, 2009), all clustered on the short arm of chromosome 11.
SAA1 and SAA2 genes, referred to as acute-phase genes share
approximately 95% overall sequence identity in their promoter
regions, exons, and introns (Uhlar et al, 1994). Earlier studies have
shown an association between high SAA concentration and various
human malignancies (Skinner et al, 1979; Yamada, 1999).
However, it is only recently that SAA has been proposed as a
potentially useful biomarker to monitor patients harbouring
human tumours including gastric and nasopharyngeal cancer
(Cho et al, 2004; Chan et al, 2007). Moreover, in lung cancer
patients, using mass spectrometry and proteomic technologies,
Received 3 March 2009; revised 8 May 2009; accepted 18 May 2009;
published online 16 June 2009
*Correspondence: Dr AD Santin, Department of Obstetrics, Gynecology
and Reproductive Sciences, Yale University School of Medicine, Rm. 305
LSOG, 333 Cedar Street, PO Box 208063, New Haven, CT, 06520-8063,
USA; E-mail: alessandro.santin@yale.edu
British Journal of Cancer (2009) 101, 335–341
& 2009 Cancer Research UK All rights reserved 0007– 0920/09 $32.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSAA was identified as the top differentially expressed protein able
to differentiate the serum of patients from the serum of healthy
individuals (Howard et al, 2003).
One major problem with the use of SAA, an acute-phase
reactant, as a potential serum marker in human cancer patients, is
the fact that its elevation in the serum of patients is suggested to be
of liver origin rather than a tumour–cell product (Diamandis,
2004). Indeed, SAA level in the blood may elevate up to 1000-fold
when the body responds to various injuries including trauma and
various inflammations in addition to neoplasia (Diamandis, 2004).
Importantly, however, extrahepatic SAA expression has been
previously demonstrated in several histologically normal tissues,
predominantly by their epithelium (Urieli-Shoval et al, 1998,
2000). Unfortunately, only scant information regarding SAA
expression in malignant human tissues has been so far reported
and, to our knowledge, no studies have yet addressed a potential
direct secretion of SAA by human endometrial tumours. This
report represents the first investigation examining SAA 1
expression and secretion in human serous papillary endometrial
carcinoma, the most aggressive variant of endometrial cancer.
PATIENTS AND METHODS
Primary tumours
Fresh tumour samples were derived from primary specimens
staged according to the FIGO operative staging system. Only
specimens with 475% tumour content were used in the RT–PCR
experiments. Briefly, fresh tumour biopsies from 16 USPC
(obtained from seven Caucasian and nine African-American
patients age 65±8: mean±s.d.) were obtained under approval of
the Institutional Review Board at the time of surgery and analysed
for SAA expression. Patient characteristics from which tumour
biopsies were obtained included 2 stage I, 7 stage III and 7 stage IV
patients. Total abdominal hysterectomy, bilateral salpingo-
oophorectomy and lymph node dissection were performed in all
endometrial cancer patients. Normal endometrial control cell
samples (NEC) were obtained from biopsies of benign hysterec-
tomy specimens obtained from women of similar age. Three
primary USPC cell lines (i.e., USPC-ARK-1, USPC-ARK-2, USPC-
ARK-3) were also established as short-term cultures following
previously reported standard tissue culture techniques (Santin
et al, 2004, 2005). RNA extraction was performed at a tumour–cell
confluence of 50–80% after a minimum of two to a maximum of
20 passages in vitro. The epithelial nature and the purity of tumour
cultures was verified by immunohistochemical staining and flow
cytometric analysis with antibodies against cytokeratin and
vimentin as previously described (Santin et al, 2004, 2005). Only
primary cultures which had at least 90% viability and contained
499% epithelial cells were used for SAA quantification by a
sensitive bead-based immunoassay, as described below.
RNA extraction and quantitative real-time PCR
RNA isolation from all primary snap frozen samples including
16 primary USPC as well as three normal endometrial cell controls
was performed using TRIzol Reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions. Quantitative
PCR was done with a 7500 Real-Time PCR System using the
manufacturer’s recommended protocol (Applied Biosystems,
Foster City, CA, USA) to evaluate the expression of SAA in all
the samples. Each reaction was run in triplicate. Briefly, 5mgo f
total RNA from each sample was reverse transcribed using
SuperScript III first-strand cDNA synthesis (Invitrogen). Five
microliters of reverse-transcribed RNA samples (from 500mlo f
total volume) were amplified by using the TaqMan Universal PCR
Master Mix (Applied Biosystems) to produce PCR products
specific for SAA. The primers for SAA were obtained from Applied
Biosystems (Assay ID Hs00761940_s1). Owing to the approxi-
mately 95% sequence homology between SAA1 and SAA2, these
primers are reported to recognise both forms of SAA. The
comparative threshold cycle (Ct) method (Applied Biosystems)
was used to determine the gene expression in each sample relative
to the value observed in the lowest nonmalignant endometrial
epithelial cell sample, using glyceraldehyde-3-phosphate dehydro-
genase (Assay ID Hs99999905_m1) RNA as internal controls.
Intracellular flow cytometry
The mouse anti-human anti-SAA1 monoclonal antibody (i.e., clone
mcl, DAKO Corporation; Carpinteria, CA), was used for our flow
cytometry study. Briefly, freshly established USPC cell lines and
control cells were fixed with 2% paraformaldehyde in PBS, washed
and permeabilised by incubation in PBS plus 1% BSA and 0.5%
saponin (S-7900, Sigma, St Louis, MO, USA) for 10min at room
temperature. Tumour cells were stained with anti-SAA MAb and
isotype-matched controls (DAKO, Carpinteria, CA, USA). After
staining, cells were washed twice with PBS plus 0.5% BSA.
Secondary goat-anti-mouse antibody (IgG1-FITC, cat no. 349031,
Beckton Dickinson, San Jose, CA, USA) was then added for 30min
at 41C. Cells were then washed twice with PBS plus 0.5% BSA.
Analysis was conducted with a FACScalibur utilising CellQuest
software (Beckton Dickinson).
SAA immunostaining of formalin-fixed tumour tissues
Formalin-fixed paraffin-embedded normal endometrial control
tissues (five samples) and endometrial tumour tissues (eight
samples) including the tumours from which the three primary
USPC cell lines were established were evaluated by standard
immunohistochemical staining for SAA expression. Study blocks
were selected after histopathologic review by a surgical pathologist.
The most representative block was selected for each specimen.
Briefly, deparaffinised and rehydrated sections were treated
according to the manufacturer’s instructions (DAKO). The anti-
body was diluted 1:20 in DAKO Antibody Diluent and incubated
at pH 9.0 for half an hour at room temperature. DAKO Envision
system was used for secondary detection and colour was developed
using DAB chromogen (DAKO) for 5min followed by counter-
staining with haematoxylin. The anti-SAA monoclonal antibody
used (i.e., clone mcl, DAKO), was directed against SAA 1. The
preparation and specificity of this antibody has been previously
described and demonstrated (Gutfeld et al, 2006). Colour was
developed using AEC substrate (Zymed Laboratories Inc., South
San Francisco, CA, USA) for 10min followed by counterstaining
with haematoxylin. Negative controls included replacement of the
primary antibodies by PBS and by normal mouse isotype-matched
IgG (IgG2a, kappa; DAKO). Liver sections were used as positive
controls. SAA intensity of staining was graded semi-quantitatively
as 0 (negative¼no staining), 1þ (focal, weak cytoplasmic
staining), 2þ (diffuse weak, or focal moderate cytoplasmic
staining), or 3þ (diffuse, strong cytoplasmic staining).
Analysis of SAA secretion in tumour samples
To evaluate the potential secretion of SAA by primary USPC,
supernatants obtained from USPC-ARK-1, USPC-ARK-2, and
USPC-ARK-3 as well as multiple control cell lines including
normal human fibroblasts, EBV-transformed B cells (LCL) and
cervical carcinoma cell lines were evaluated by a sensitive bead-
based immunoassay (Millipore Corp. Danvers, MA, USA). Briefly,
tumour supernatants to be tested for SAA secretion were collected
by primary tumour cell lines seeded at a density of 1 10
5 cells per
ml in tissue culture Petri dishes (Corning, Corning, NY, USA) in
RPMI-1640 media, supplemented with 10% FBS (i.e., USPC and
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i.e., cervical cancer cell lines). After 72h incubation at 371C,
supernatants were aspirated, rendered cell-free by centrifugation at
1500 r.p.m. for 10min, and stored at  201C before being analysed
for SAA by a bead-based immunoassay (see below).
Measurement of SAA concentration in serum samples
SAA concentration was quantified in the serum of 51 apparently
healthy women (age 59.6±10.9: mean±s.d.), 42 women with
benign diseases (i.e., 22 uterine fibroids, 8 ovarian cysts and
12 endometrial polyps, age 51.2±15.6), and 30 women with
histologically proven primary USPC (age 64.7±9.5), including
seven stage I, four stage II, eight stage III and 11 stage IV patients,
by a commercially available bead-based immunoassay (Lincoplex
kit, acute-phase proteins, Millipore). In brief, the assay is based on
conventional sandwich assay technology. The antibody specific to
SAA is covalently coupled to Luminex microspheres. After a final
wash, the beads are resuspended in buffer and read on a Bio-Rad
Luminex
100 Instrument to determine the concentration of SAA. All
specimens were tested in replicate wells. Results are reported as the
mean of the replicates. Serum samples from all patients were
collected before surgery and stored at  801C until analysis.
Statistical analysis
For q-RT–PCR data, the right-skewing was removed by taking
copy number ratios relative to the lowest-expressing NEC sample
(‘relative copy numbers’), log2 transforming them to DCts, and
comparing the results through unequal variance t-test for the
USPC vs NEC difference. Group means with 95% confidence limits
(CIs) were calculated by computing them on the DCts and then
reverse-transforming the results to obtain means (95% CIs) of
relative copy numbers. The analyses of differences among super-
natants obtained from tumour cultures with different histologies,
and among expression levels measured by flow cytometry and
IHC, were performed using the Wilcoxon–Mann–Whitney
(WMW) test. SAA serum concentrations among the different
groups of patients (i.e., healthy controls, benign gynaecologic
diseases, and USPC) were summarised as medians (with rank-
based 95% CIs) and ranges, and compared for pairwise differences
through receiver operating characteristic (ROC) analysis in
conjunction with the WMW test. Within the USPC group, the
ability of serum SAA to distinguish between advanced-stage
(III–IV) and early-stage (I–II) disease was assessed in detail
using ROC analysis and tested by WMW test. NCSS (Number
Cruncher Statistical Systems, Kaysville, UT) was used for the ROC
analyses, Excel (Microsoft Corp., Redmond, WA, USA) was used
for generating graphs, and SPSS (SPSS Inc., Chicago, IL, USA) was
used for all other statistical analyses. A 5% significance level was
used for all statistical comparisons.
RESULTS
SAA expression in snap frozen USPC by quantitative
real-time PCR
USPC are rare tumours, which may present in either pure forms, or
admixed with endometrioid or clear cell tumour cells (i.e., mixed
USPC). To minimise the risk of contamination of USPC RNA with
that of normal cells or tumour cells with different histology, we
extracted RNA to be evaluated for SAA expression by RT–PCR
from 16 primary USPC with single-type differentiation (i.e., pure
USPC). A comparison of the q-RT–PCR data for SAA in USPC vs
NEC as controls is shown in Figure 1. Significant expression
differences between USPC and NEC were readily apparent
(Figure 1). Fifteen (94%) of the 16 USPC samples, compared with
none (0%) of the three NEC samples, were found positive (410)
for SAA expression by RT–PCR. Relative copy numbers in NEC
control samples had a mean (95% CI) of only 2.21 (0.315–15.5)
and ranged from 1.00 to 4.80. In contrast, relative copies in USPC
samples had a mean (95% CI) of 162 (55.8–470) and ranged from
2.76 to 2745. The fold change in mean relative copy numbers was
73.2 (Figure 1; P¼0.0002).
Intracellular SAA expression in USPC cell lines by
flow cytometry
To determine whether the high expression of SAA gene detected
by q-RT–PCR assays in flash frozen USPC also results in high
expression of the SAA protein, we performed intracellular flow-
cytometry analysis of SAA protein expression in three primary
USPC established as short-term cultures in vitro in our laboratory.
As shown in Table 1, all three primary USPC culture cell lines were
found positive for intracellular SAA expression by flow cytometry
(i.e., 100% positive cells; mean fluorescence intensity range from
40 to 77) (Table 1). In contrast, significantly lower expression of
SAA was detected in Epstein–Barr transformed B cells (LCL) and
cervical cancer cell lines (CVX) used as controls (i.e., 65–71%
positive cells; mean fluorescence intensity range from 11 to 20 and
69–84% positive cells; mean fluorescence intensity range from 9 to
15, respectively) by flow cytometry (P¼0.03 for both USPC vs LCL
and USPC vs CVX, Table 1).
SAA expression by immunohistochemistry in USPC
To evaluate whether the high SAA expression detected by flow
cytometry on primary USPC cell lines was compared with the
expression of SAA of the USPC specimens from which the primary
tumour cell lines were derived (i.e., USPC-ARK-1, USPC-ARK-2,
and USPC-ARK-3) and/or whether in vitro expansion conditions
may have modified protein expression, we evaluated SAA by
immunohistochemical staining on formalin-fixed tumour tissue.
As representatively shown in Figure 2 for USPC-ARK-1 and USPC-
ARK-2, SAA was detected by IHC in all three USPC tissues. The
intensity of staining for SAA was significantly higher among the
tumour specimens compared with normal endometrial controls
(Po0.001). Indeed, although all USPC tumours tested showed
moderate (2þ) or strong (3þ) cytoplasmic positivity, normal
control endometrial cells were found consistently negative for SAA
expression whereas normal liver tissue (i.e., positive control) was
found strongly positive for SAA expression (Figure 2).
0.1 1 10 100 1000 10 000
SAA mRNA, relative copy number
NEC
USPC
Figure 1 SAA mRNA copy number by quantitative RT–PCR in three
normal endometrial control cell samples (NEC) and 16 uterine serous
papillary carcinomas (USPC) snap frozen biopsies. The horizontal axis
represents the relative number of copies compared with the lowest-
expressing NEC (value of one). Circles denote individual observations,
whereas diamonds with error bars represent group means with their
95% confidence intervals (CIs). Computation of means and 95% CIs are
described in the text under Methods.
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Primary short-term tumour cultures may provide an opportunity
to study differential SAA secretion between highly enriched
populations of tumour-derived epithelial cells. Cell-free super-
natants from freshly isolated gynaecologic malignancies including
three USPC and three squamous cervical carcinoma cell lines, as
well as cultures of normal human fibroblasts and EBV cell lines,
were collected and analysed for SAA expression levels by a
sensitive bead-based immunoassay. Because prolonged passages
in vitro are known to alter the physiology and phenotype of
primary tumour cells, we performed all our experiments with
highly purified tumour cells and normal cells (i.e., fibroblasts and
EBV-transformed B cells) grown for less than 20 passages in vitro.
Growth control medium was always analysed at the same time.
In this regard, KSFM and RPMI-1640 media containing 10% fetal
bovine serum had no detectable endogenous levels of SAA
immunoreactivity (data not shown). All three primary USPC
tumour cell lines tested secreted large amounts of SAA (mean-
11.2ngml
 1, range: 0.7–30.3ngml
 1 per 10
5 cells per 72h). In
contrast, undetectable to low secretion was identified in the
supernatant of normal human fibroblasts (mean¼0.12ngml
 1),
EBV-transformed B cells (mean¼0.16ngml
 1) or in those of three
primary cervical carcinoma cell lines (i.e., not detectable) run in
parallel (Po0.001).
Serum SAA concentration in USPC and noncancer patients
To investigate whether SAA is detectable in the serum of patients
harbouring USPC, samples from 30 USPC patients, 51 healthy
female controls and 42 women harbouring benign gynaecologic
diseases were evaluated by a sensitive bead-based immunoassay
(Millipore). SAA serum levels (mgml
 1) from 51 healthy female
controls had a median (95% CI) of 6.0 (4.0–8.9) and ranged from
1.6 to 169, whereas 42 patients with benign gynaecologic diseases
had a median (95% CI) of 6.0 (4.2–8.1) and ranged from 1.1 to 189;
their distributions were not statistically significantly different (area
under ROC curve ¼0.506; P¼0.92) (Table 2 and Figure 3). In
contrast, serum SAA values from 30 USPC patients had a median
(95% CI) of 15.6 (9.2–56.2) and ranged from 2.1 to 4000; these
values were statistically significantly higher than those in the
healthy group (area under ROC curve¼0.732; P¼0.0005) and
benign group (area under ROC curve¼0.739; P¼0.0006). It is
worth noting that in our series of USPC patients, all of whom were
surgically staged, the majority were found to harbour advanced-
stage disease (i.e., 63% stage III–IV). Thus, although most of our
patients were considered to have clinical stage I disease before
surgery, they were later up-staged at the time of comprehensive
surgical staging laparotomy. In this regard, when preoperative SAA
serum levels in USPC patients were analysed by stage, we found
higher SAA serum levels in patients harbouring the most advanced
Figure 2 Representative immunohistochemical staining for SAA on NEC paraffin-embedded specimen (A,  200), USPC-ARK-1 and USPC-ARK-2
(B and C,  400), and a liver biopsy (D,  100). NEC 1 showed negative staining for SAA whereas prominent cytoplasmic staining was detectable in
representative tissue blocks from both USPC. Strong cytoplasmic SAA positivity was evident in the positive control (i.e., liver).
Table 1 Intracellular SAA expression in USPC and control cell lines
Binding of MAb
Tumour line designation Histology Percentage of epithelial cells Percentage of cells MFI
USPC-ARK1 Serous 499 100 40
USPC-ARK2 Serous 499 100 55
USPC-ARK3 Serous 499 100 77
CVX-1 Squamous 499 79 9
CVX-2 Squamous 499 69 11
CVX-3 Squamous 499 84 15
LCL-1 B cells 0 65 20
LCL-2 B cells 0 71 11
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or Stage IV disease had SAA levels above the 15.6-mgml
 1 median,
whereas 10 (91%) of 11 patients with Stage I or Stage II disease had
SAA levels below the median (Figure 4A). These results correspond
to 74% sensitivity and 91% specificity using the 15.6-mgml
 1
median to distinguish advanced stage (III–IV) from early-stage
(I–II) USPC. ROC analysis of serum SAA’s staging potential
(Figure 4B) showed that dichotomising SAA at or near 15.6mgml
 1
maximised the sum of sensitivity and specificity in this data set.
The area under the ROC curve was 0.837 (P¼0.0024). Importantly,
high (415.6mgml
 1) preoperative serum SAA values were
predictive for advanced disease in 50% (4/8) of stage III patients
and 91% (10/11) of stage IV patients with USPC.
DISCUSSION
USPC represents a variant of endometrial carcinomas charac-
terised by a highly aggressive biological behaviour. The micro-
scopic criteria for USPC diagnosis were first outlined by
Hendrickson et al (1982). Classically, the neoplastic epithelium is
characterised by serous differentiation with psammoma bodies
present and with predominantly papillary architecture although
solid areas can be focally detected (Hendrickson et al, 1982).
Cytologically, pleomorphism, grade III nuclear atypia with
prominent nucleoli and vesicular chromatin pattern, and a high
mitotic activity are detected. Clinically, USPC has a propensity for
early intraabdominal and lymphatic spread even at presentation
(Hendrickson et al, 1982). Unlike the histologically indistinguish-
able serous ovarian carcinomas, USPC is a chemoresistant disease,
because its onset with responses to combined cisplatinum-based
chemotherapy is on the order of 20% and of short duration
(Hendrickson et al, 1982; Goff et al, 1994; Carcangiu and
Chambers, 1995; Chan et al, 2003). The survival rate is dismal,
even when USPC is only a minor component of the histologically
more common endometrioid adenocarcinoma, and widespread
metastasis and death may occur even in those cases in which
tumour is confined to the endometrium or to an endometrial
polyp. The overall 5-year survival is about 30% for all stages,
and the recurrence rate after surgery is extremely high (50–80%).
The identification of biomarkers that can be used for early
diagnosis, monitoring, and prediction of response to treatment
in USPC might greatly contribute to the improvement of clinical
management and outcomes of these patients. Unfortunately, no
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Figure 3 Distributions of serum SAA levels from 51 healthy subjects
(bottom series), 42 benign-disease subjects (middle series), and 30 USPC
patients (top series). Horizontal axis shows SAA in mgml
 1. Circles show
individual serum SAA levels, whereas ‘split-X’ symbols with error bars
denote group medians with their rank-based 95% confidence intervals.
The accompanying Table 4 contains the numerical values of medians,
confidence intervals, and ranges, along with Mann–Whitney–Wilcoxon
P-values and areas under ROC curves for the pairwise comparisons among
the three groups.
Table 2 Serum SAA in non-cancer (healthy), benign disease and
USPC patients
Subject group N Median (95% CI)
a Range
a
Healthy 51 6.0 (4.0–8.9) 1.6–169.2
Benign disease 42 6.0 (4.2–8.1) 1.1–189.9
USPC 30 15.6 (9.2–56.2) 2.1–4000
Pairwise comparison Area under ROC curve
b P-value
c
Healthy vs benign 0.506 0.917
Healthy vs USPC 0.732 0.0005
Benign vs USPC 0.739 0.0006
aMedians, 95% confidence intervals, and ranges of serum SAA are in mgml
 1.
bValues
near 0.50 denote highly overlapping distributions; values near 1.00 denote highly
separated distributions.
cP-values are from the two-sided Wilcoxon–Mann–Whitney
test of the indicated comparison.
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Figure 4 (A) Displays the distribution of serum SAA (mgml
 1; horizontal axis) in high-stage (III-IV; top half) vs low-stage (I–II; bottom half) USPC patients.
The heavy vertical dashed line denotes the median SAA (15.6mgml
 1) among all 30 patients. Fourteen of 19 high-stage patients had serum SAA above the
median (74% sensitivity), whereas 10 of 11 low-stage patients had serum SAA below the median (91% specificity). (B) Displays the empirical Receiver
Operating Characteristic (ROC) curve of the data in Panel A; the grey ellipse in Panel B circles the combination of sensitivity (74%) and specificity (91%)
achieved using median SAA as a threshold to diagnose high-stage disease, and shows that this threshold maximises the sum of sensitivity and specificity in
these patients. The area under the ROC curve was 0.837 (Mann–Whitney P¼0.0024).
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identified for this disease. In this regard, although it has been
previously reported that the elevation of CA 125 level may be
associated with an increase in the incidence of metastatic dis-
ease in endometrial tumours with endometrioid histology (Soper
et al, 1990; Dotters, 2000), this marker appears to have limited
utility in monitoring the effects of adjuvant therapy or in predict-
ing tumour recurrence in USPC patients (Price et al, 1998). This
report represents the first evaluation of SAA as a novel biomarker
in USPC.
In this study, we have quantified SAA expression by RT–PCR
in snap frozen USPC specimens. In addition, we have studied
SAA protein expression and secretion in multiple primary
gynaecologic malignancies including USPC and cervical cancer
tumour cultures. We have confirmed the purity of the tumour
cells in our short-term cultures by differential counts of Giemsa-
stained cytospin slides as well as by cytokeratin expression using
immunohistochemical techniques (data not shown). Our fresh
tumour samples contained over 99% tumour cells. Finally, we have
studied SAA levels in 123 serum samples derived from healthy
donors, patients harbouring benign gynaecologic tumours and
USPC patients.
We report for the first time a high level of expression of the SAA
gene in USPC. Indeed, SAA gene expression was significantly
higher in USPC when compared with NEC by RT–PCR. The
average copy number of SAA-gene mRNA was 73 times higher in
USPC compared with NEC cells. Consistent with these findings,
highly purified primary USPC cultures were found positive for
intracellular expression of SAA by flow cytometry as well as IHC
and, importantly, were able to secrete high levels of SAA in vitro as
detected by a sensitive bead-based immunoassay. In contrast, SAA
was not detected in any of the three CVX cell lines tested and
negligible levels were found in the culture supernatants of normal
human fibroblasts cultures used as controls. Thus, taken together,
our data highlighted for the first time a major tumour expression
and secretion of SAA directly by USPC. More importantly, these
results support our hypothesis that, in USPC patients, SAA is not
only a liver-secreted protein but is also a USPC cell product. Of
interest, Gutfeld et al (2006) have recently reported on SAA
expression in normal, dysplastic, and neoplastic colonic mucosa.
Using in situ hybridisation and IHC, they demonstrated the local
and the differential expressions of SAA in human colon cancer
tissues when compared with normal colonic mucosa. Furthermore
they showed progressively higher SAA positivity through the
different stages of dysplasia to overt carcinoma (Gutfeld et al,
2006). These findings in human colon carcinoma combined with
our results in USPC seem to suggest a novel role for SAA autocrine
production in colonic and endometrial tumorigenesis. In this
regard, although the biological importance of SAA in USPC
patients is not well understood, previous reports have suggested
multiple important biologic functions of SAA. Indeed, SAA has
been previously reported to be involved in cholesterol metabolism
and transport, inhibition of lymphocyte, and endothelial cell
proliferation, depression of the immune system, inhibition of
platelet aggregation, and induction of adhesion, migration, and
tissue infiltration of monocytes, neutrophils, lymphocytes, and
mast cells (Malle et al, 2009).
Importantly, when SAA levels were quantified in the serum of
USPC patients, we found elevated levels in USPC patients when
compared with the levels found in healthy women. Furthermore,
in the limited number of USPC patients where sequential serum
samples were available (i.e., two patients), a decrease in SAA levels
was observed post-operatively (data not shown). These in vivo
data accord with our in vitro results from highly purified USPC
primary cultures, and suggest that SAA is actively secreted by
biologically aggressive USPC cells in vitro, and potentially in vivo.
Importantly, we found no significant elevation of SAA in the
serum of patients harbouring benign gynaecologic disease when
compared with healthy female patients. We conclude that SAA
may be a promising biomarker for early detection of recurrent
USPC disease and for monitoring USPC response to adjuvant
therapy.
It is worth noting that in our series of USPC patients, all of
whom were surgically staged, the majority (63%) were found to
harbour advanced disease. Thus, although most of our patients
were considered to have clinical stage I disease before surgery, they
were later up-staged at the time of comprehensive surgical staging
laparotomy. Of interest, when preoperative SAA serum levels in
our USPC patients were analysed by stage we found such levels to
correlate with the stage of the disease (i.e., patients harbouring
more surgically advanced stage disease that had significantly
higher SAA levels when compared with patients harbouring stage I
and stage II disease). High (415.6mgml
 1) preoperative serum
SAA values in patients otherwise clinically diagnosed with early-
stage USPC were predictive for stage III and stage IV disease in
50% (four out of eight) and 91% (10 out of 11) of the USPC
patients, respectively. Indeed, dichotomising serum SAA at or near
15.6mgml
 1 achieved 74% sensitivity with 91% specificity for
distinguishing advanced- (III–IV) from early-stage (I–II) disease.
Thus, although larger studies that include more USPC patients
harbouring surgically confirmed early- and late-stage disease will
be necessary to confirm these findings, high SAA serum levels at
the time of clinical diagnosis and before surgery may predict
advanced-stage disease at the time of the staging laparotomy in the
majority of patients. In this regard, it is important to point out
that, because of the propensity of USPC to rapidly manifest
extrauterine disease (i.e., positive lymph node metastases or
spreading to the abdominal cavity), the USPC series reported here
is likely most representative of the advanced stage disease
commonly found in surgically staged USPC patients. In agreement
with our data, Goff et al (1994) found 75% of patients with clinical
stage I/II USPC to have extracorporeal disease when compre-
hensively staged. Similarly, Bristow et al demonstrated 74.4% of
USPC patients to have advanced-stage disease following ovarian
cancer-type surgical staging (Bristow et al, 2001). These findings
were also corroborated in studies by O’Hanlan et al (1990) and
Geisler et al (1999).
Several other potentially useful markers, including the human
kallikrein enzymes hK6 and hK10 and cytokines such as
interleukin-6, have recently been shown to be highly differentially
expressed and secreted by USPC (Bellone et al, 2005; Santin et al,
2005a, 2006). It is thus possible that in analogy to what has recently
been shown in ovarian cancer (Mor et al, 2005), the simultaneous
evaluation of multiple markers such as SAA, hK6, hK10, and IL-6
by a multiplex, bead-based immunoassay system may ultimately
allow the development of a test endowed with high specificity and
sensitivity for the detection of USPC. This possibility is currently
being investigated in our laboratory.
In conclusion, we report here the first evidence that SAA is
highly expressed in USPC, it is actively secreted in vitro, and that
high concentrations of SAA are present in the serum of USPC
patients. Moreover, we have shown that high preoperative serum
SAA levels in USPC patients clinically diagnosed with early-stage
disease are predictive of more advanced stage disease at the time
of comprehensive surgical staging. Our results strongly support
the hypothesis that SAA may be used as a biomarker for this
highly aggressive variant of endometrial cancer. Indeed, although
SAA does not fulfil the criteria for an ‘ideal marker’, we believe
that it has potential value in the initial assessment of patients
harbouring USPC as well as in the potential monitoring of
therapeutic results. The current availability of a highly sensitive
and specific assay for measuring SAA protein concentration in
serum, either alone or in combination with multiple additional
biomarkers, will facilitate further studies to validate the clinical
usefulness of the circulating levels of SAA for the management of
patients with USPC.
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